Fig. 5From: Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine a Hyperemic myocardial blood flow (MBF) and b coronary flow reserve in type 2 diabetic patients at baseline and after 26-weeks of exenatide [dots; open dots (mean ± SD)] versus insulin glargine [squares; open squares (mean ± SD)]Back to article page